Research programme: endocan inhibitors - Endotis

Drug Profile

Research programme: endocan inhibitors - Endotis

Alternative Names: Endocan inhibitors research programme - Endotis; EP 16; EP 208

Latest Information Update: 03 Oct 2015

Price : $50

At a glance

  • Originator Endotis Pharma
  • Class Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jun 2004 Preclinical trials in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top